活動性乾癬性関節炎と中等度以上の尋常性乾癬を有する患者におけるイキセキズマブとアダリムマブの有効性と安全性比較: 無作為化 SPIRIT-H2H 試験の52週結果
Dermatol Pract Concept. 2022 doi: 10.5826/dpc.1202a104
Ixekizumab (IXE)-treated patients achieved significantly greater simultaneous PASI100 and ACR50 responses through W52 versus adalimumab (ADA)-treated, confirming IXE as an efficacious and safe treatment. This study investigated the efficacy and safety of IXE and ADA in the subgroup of patients with PsA and moderate-to-severe PsO through W52.
A comparison of the results of this analysis with those of other studies confirms the efficacy of IXE in treating nail PsO in patients with moderate-to-severe PsO, irrespective of concomitant active PsA. These results increase awareness of available treatment options and inform evidence-based clinical decisions for patients with active PsA and moderate-to-severe PsO.
Keywords:
